Rain Oncology Inc (NAS:RAIN)

$ 1.21 0 (0%) Market Cap: 44.02 Mil Enterprise Value: -32.85 Mil PE Ratio: 0 PB Ratio: 0.65 GF Score: 22/100

Q2 2023 Rain Oncology Inc Earnings Call Transcript
Aug 10, 2023

$1.18 (-2.48%)

Earnings
Rain Oncology Inc to Discuss the Topline Data from Phase 3 MANTRA Trial Call Transcript
May 22, 2023
Q1 2023 Rain Oncology Inc Earnings Call Transcript
May 11, 2023

$9.28 (+1.42%)

Earnings
Q4 2022 Rain Oncology Inc Earnings Call Transcript
Mar 09, 2023

$8.44 (-8.66%)

Earnings
Rain Oncology Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 21, 2023
Rain Oncology Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Rain Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$5.78 (-0.52%)

Earnings
Q2 2022 Rain Therapeutics Inc Earnings Call Transcript
Aug 04, 2022

$7.1 (+5.03%)

Earnings
Q1 2022 Rain Therapeutics Inc Earnings Call Transcript
May 04, 2022

$3.44 (-8.02%)

Earnings

Rain Oncology Inc to Discuss the Topline Data from Phase 3 MANTRA Trial Call Transcript

May 22, 2023 / 12:30PM GMT

Release Date Price: $1.22 (-87.71%)

Transcript

Operator

Greetings, and welcome to the Rain Oncology Phase III Topline Results Data Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Dan Ferry, Managing Director of LifeSci Advisors. Please go ahead, sir.

Daniel Ferry

LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, operator. Good morning, and thank you for joining us on the conference call to discuss the topline results of Rain's Phase III MANTRA trial of milademetan in dedifferentiated liposarcoma. On the call with me today are Avanish Vellanki, Co-Founder, Chairman and Chief Executive Officer of Rain Oncology; Dr. Robert Doebele, Co-Founder and Chief Scientific Officer; Dr. Richard Bryce, Chief Medical Officer; and Nelson Cabatuan, SVP of Finance.

Earlier this morning, Rain issued a press release with topline data from the Phase III MANTRA study. This release is accessible in the News and Press Releases section of Rain's website at www

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.